How big is the congenital adrenal hyperplasia market today, and what are its future growth expectations?
The congenital adrenal hyperplasia market size has grown strongly in recent years. It will grow from $0.47 billion in 2024 to $0.50 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of congenital adrenal hyperplasia, growing adoption of corticosteroid therapies, rising healthcare expenditure, increasing focus on pediatric care, and increase government initiatives and reimbursement policies.
The congenital adrenal hyperplasia market size is expected to see strong growth in the next few years. It will grow to $0.66 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing demand for personalized medicine, rising incidence of genetic disorders, increasing research on congenital adrenal hyperplasia treatments, increasing healthcare investments, increasing use of telemedicine in congenital adrenal hyperplasia management. Major trends in the forecast period include advancements in healthcare infrastructure, advancements in molecular diagnostics, development of enzyme replacement therapies, development of long-acting corticosteroid formulations, and advancements in genetic screening.
Get Your Free Sample of The Global Congenital Adrenal Hyperplasia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21157&type=smp
What have been the primary factors driving the congenital adrenal hyperplasia market’s growth?
The rise in demand for gene therapy is expected to propel the growth of the congenital adrenal hyperplasia market going forward. Gene therapy refers to a medical technique that involves the modification or manipulation of an individual’s genes to treat or prevent disease. The rise in demand for gene therapy is attributed to advancements in genetic research and biotechnology, which have enabled more precise and targeted treatments for genetic disorders, cancers, and other chronic diseases. The congenital adrenal hyperplasia (CAH) disorder, which is caused by mutations in genes responsible for adrenal hormone production, serves as a critical focus in gene therapy by offering opportunities for targeted genetic interventions to correct the underlying genetic defects and restore normal hormone function. For instance, in April 2024, according to the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, out of the 1,023 gene therapies in development for rare diseases, eight of the top 10 rare diseases were oncological. The second quarter of 2024 saw the initiation of 76 gene therapy trials, a 25% increase from the previous quarter. Therefore, the rise in demand for gene therapy is driving growth in the congenital adrenal hyperplasia market.
What are the key segments within the congenital adrenal hyperplasia market?
The congenital adrenal hyperplasia market covered in this report is segmented –
1) By Type: Classic Congenital Adrenal Hyperplasia, Non-Classic Congenital Adrenal Hyperplasia
2) By Treatment And Diagnosis: Diagnosis, Treatment
3) By End-Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
Subsegments:
1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia, Simple Virilizing Classic Congenital Adrenal Hyperplasia
2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia, Mild Non-Classic Congenital Adrenal Hyperplasia
Order your report now for swift delivery
Which key players are shaping the congenital adrenal hyperplasia market?
Major companies operating in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., Crinetics Pharmaceuticals Inc.
How will emerging trends drive the congenital adrenal hyperplasia market throughout the forecast period?
Major companies operating in the congenital adrenal hyperplasia market are focusing on developing innovative treatments such as CRF1 receptor antagonists to regulate cortisol production and reduce adrenal androgen excess. CRF1 receptor antagonist refers to a drug that blocks the corticotropin-releasing factor 1 (CRF1) receptor to regulate the body’s stress response and reduce excessive adrenal androgen production in conditions such as congenital adrenal hyperplasia. For instance, in December 2024, Neurocrine Biosciences, Inc., a US-based biopharmaceutical company, received FDA approval for crenessity (crinecerfont), the first new treatment for congenital adrenal hyperplasia (CAH) in 70 years. This oral medication acts as a selective antagonist of corticotropin-releasing factor type 1 receptors, helping to control excess adrenocorticotropic hormone (ACTH) and adrenal androgens while allowing for reduced glucocorticoid doses. Approval was based on data from the CAHtalyst Phase 3 studies, which showed significant efficacy in lowering androgen levels. Crenessity is expected to be available soon, marking a significant advancement in CAH management.
How do regional factors impact the congenital adrenal hyperplasia market, and which region is the largest contributor?
North America was the largest region in the congenital adrenal hyperplasia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Congenital Adrenal Hyperplasia Market Report 2025 Offer?
The congenital adrenal hyperplasia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Congenital adrenal hyperplasia refers to a group of inherited disorders affecting adrenal gland function due to enzyme deficiencies, primarily 21-hydroxylase. Congenital adrenal hyperplasia is managed through hormone replacement therapy to normalize cortisol and aldosterone levels, suppress excess androgen production, and address associated symptoms such as electrolyte imbalance and abnormal physical development.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21157
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
